IP Library › Granted Patent US 9,808,436
Granted Patent B2
US 9,808,436 · App. 15/271,460 · Granted Nov 7, 2017

Treatment of intrahepatic cholestatic diseases

Inventors: Pol Boudes (Fremont, CA); Charles A. McWherter (Oakland, CA)
Assignee: CymaBay Therapeutics, Inc.
A61K31/192A61K31/09
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,808,436
App. No.
15/271,460
Granted
Nov 7, 2017
Kind
B2
Abstract

Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.

Claims (9)

1. A method of treating primary sclerosing cholangitis by administering to a subject in need thereof a therapeutically effective amount of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)-phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof.

2. The method of claim 1 where the (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl) -phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof is administered orally.

3. The method of claim 1 where the daily dose of the (R)-2-(4-((2-ethoxy -3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof (when calculated as the free acid) is 20-200 mg.

4. The method of claim 3 where the daily dose of the (R)-2-(4-((2-ethoxy -3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof (when calculated as the free acid) is 50-100 mg.

5. The method of claim 1 where the(R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl) -phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof is administered once/day.

6. “A method of treating primary sclerosing cholangitis by orally administering to a subject in need thereof a therapeutically effective amount of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)-phenoxy)propyl)thio)-2-methylphenoxy)acetic acid L -Lysine dihydrate salt.

7. The method of claim 6 , wherein the daily dose of the (R)-2-(4(2-ethoxy -3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid L -Lysine dihydrate salt (when calculated as the free acid) is 20-200 mg.

8. The method of claim 7 , where the daily dose of the (R)-2-(4(2-ethoxy -3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid L -Lysine dihydrate salt (when calculated as the free acid) is 50-100 mg.

9. The method of claim 6 where the(R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl) -phenoxy)propyl)thio)-2-methylphenoxy)acetic acid L -Lysine dihydrate salt is administered once/day.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Oct 3, 2024
From: ABW CYCLOPS SPV LP
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 069833/0155 →
Continuity (3)
Continuation 14663027 · Mar 19, 2015
Provisional Application 61968037 · Mar 20, 2014
Related Publication 20170014363A1 · Jan 19, 2017